Health Catalyst (HCAT) Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last year. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HCAT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HCAT, but not buy additional shares or sell existing shares.
View HCAT analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year price objectives for Health Catalyst's shares. Their HCAT share price forecasts range from $8.00 to $18.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for HCAT or view top-rated stocks among Wall Street analysts.

Health Catalyst's stock was trading at $10.63 on January 1st, 2023. Since then, HCAT shares have increased by 12.9% and is now trading at $12.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our HCAT earnings forecast.

Health Catalyst, Inc. (NASDAQ:HCAT) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.14. The firm earned $73.87 million during the quarter, compared to the consensus estimate of $71.16 million. Health Catalyst had a negative trailing twelve-month return on equity of 17.45% and a negative net margin of 52.53%.

ETFs with the largest weight of Health Catalyst (NASDAQ:HCAT) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC), Fidelity Digital Health ETF (FDHT), SPDR FactSet Innovative Technology ETF (XITK), Invesco Raymond James SB-1 Equity ETF (RYJ), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF) and

Health Catalyst issued an update on its second quarter 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $70.30 million-$74.30 million, compared to the consensus revenue estimate of $72.78 million.

501 employees have rated Health Catalyst Chief Executive Officer Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among the company's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Health Catalyst to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), Salesforce (CRM), Alteryx (AYX), Walt Disney (DIS), DocuSign (DOCU), Block (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology (MRVL) and PayPal (PYPL).

(HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair acted as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Health Catalyst trades on the NASDAQ under the ticker symbol "HCAT."

Health Catalyst's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.44%), First Light Asset Management LLC (3.52%), Daventry Group LP (2.91%), State Street Corp (2.48%), Geode Capital Management LLC (1.92%) and Balyasny Asset Management L.P. (1.87%). Insiders that own company stock include Anita Pramoda, Bryan Richard Hinton, Bryan Truman Hunt, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, Duncan Gallagher, James Patrick Jr Nelli, Jason Alger, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends.

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HCAT stock can currently be purchased for approximately $12.00.

Health Catalyst (NASDAQ:HCAT) has a market capitalization of $675.12 million and generates $276.24 million in revenue each year. The company earns $-137,400,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

The company employs 1,200 workers across the globe.

Health Catalyst's mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The official website for the company is www.healthcatalyst.com. The company can be reached via phone at (801) 708-6800 or via email at ir@healthcatalyst.com.